Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy

Annals of Surgery

Volumn 245, Issue 2, 2007, Pages 259-266

  Smith, Fraser M ^a   Gallagher, William M ^b   Fox, Edward ^b   Stephens, Richard B ^a   Rexhepaj, Elton ^b   Petricoin III, Emanuel F ^c   Liotta, Lance ^c   Kennedy, M John ^a   Reynolds, John V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; PROTEOME;

ACCURACY; ADULT; AGED; ALGORITHM; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DATA MINING; FEMALE; HUMAN; HUMAN TISSUE; INTESTINAL FIBROSIS; MALE; MOLECULAR WEIGHT; MULTIMODALITY CANCER THERAPY; PATIENT MONITORING; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEOMICS; RATING SCALE; RECTUM TUMOR; SUPPORT VECTOR MACHINE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT OUTCOME; TUMOR REGRESSION; VALIDATION PROCESS;

AGED; ALGORITHMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 33846536842     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000245577.68151.bd     Document Type: Article

References (52)

1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351: 1731-1740.
2. Habr-Gama A, Perez RO, Kiss DR, et al. Preoperative chemoradiation therapy for low rectal cancer: impact on downstaging and sphincter-saving operations. Hepatogastroenterology. 2004;51:1703-1707.
3. Crane CH, Skibber JM, Feig BW, et al. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer. 2003;97: 517-524.
4. Rullier E, Goffre B, Bonnel C, et al. Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum. Ann Surg. 2001;234:633-640.
5. Wheeler JM, Dodds E, Warren BF, et al. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum. 2004;47:2025-2031.
6. Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncological outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005; 241:829-836.
7. Bouzourene H, Bosman FT, Seelentag W, et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 2002;94:1121-1130.
8. Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, et al. A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum. 2003;46:298-304.
9. Habr-Gama A, Perez RO, Nadalin W, et al. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival. J Gastrointest Surg. 2005;9:90-101.
10. Theodoropoulos G, Wise WE, Padmanabhan A, et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum. 2002;45:895-903.
11. Reerink O, Karrenbeld A, Plukker JT, et al. Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemoradiotherapy. Anticancer Res. 2004;24:1217-1221.
12. Gambacorta MA, Micciche F, Corvari B, et al. Biological factors and therapeutic modulation in rectal cancer radiotherapy. Rays. 2002;27: 219-222.
13. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer. 1994;73:2680-2686.
14. Van Den Brink M, Van Den Hout WB, Stiggelbout AM, et al. Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group. J Clin Oncol. 2004;22:244-253.
15. Birgisson H, Pahlman L, Gunnarsson U, et al. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol. 2005;23:6126-6131.
16. Dahlberg M, Stenborg A, Pahlman L, et al. Cost-effectiveness of preoperative radiotherapy in rectal cancer: results from the Swedish Rectal Cancer Trial. Int J Radiat Oncol Biol Phys. 2002;54:654-660.
17. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711-717.
18. Bedrosian I, Rodriguez-Bigas MA, Feig B, et al. Predicting the nodenegative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. J Gastrointest Surg. 2004;8:56-62.
19. Zmora O, Dasilva GM, Gurland B, et al. Does rectal wall tumor eradication with preoperative chemoradiation permit a change in the operative strategy? Dis Colon Rectum. 2004;47:1607-1612.
20. Sischy B. The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys. 1985;11:1587-1593.
21. Sischy B, Doggett RL, Krall JM, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiotherapy Oncology Group study no. 8314. J Natl Cancer Inst. 1989;81:850-856.
22. Smith FM, Stephens RB, Kennedy MJ, et al. p53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92:1813.
23. Smith FM, Reynolds JV, Miller N, et al. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol. 2006;32:55-64.
24. Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol. 2005;23:1826-1838.
25. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature. 2003;425:905.
26. Conrads TP, Zhou M, Petricoin III EF, et al. Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn. 2003;3:411-420.
27. Espina V, Dettloff KA, Cowherd S, et al. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther. 2004; 4:83-93.
28. Yang S, Xiao X, Zhang W, et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer. 2005;5:83.
29. Laronga C, Becker S, Watson P, et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers. 2003;19:229-238.
30. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-577.
31. Chen YD, Zheng S, Yu JK, et al. Artificial neural networks analysis of surface-enhanced laser desorption/ionisation mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res. 2004;10:8380-8385.
32. Furey TS, Cristianini N, Duffy N, et al. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics. 2000;16:906-914.
33. Yu JK, Chen YD, Zheng S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J Gastroenterol. 2004;10:3127-3131.
34. Cortes C, Vapnik V. Support-Vector Networks. Machine Learning. 1995;20:273.
35. Yu JK, Chen YD, Zheng S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J Gastroenterol. 2004;10:3127-3131.
36. Deleted in proof.
37. Wang Y, Meng A, Lang H, et al. Activation of nuclear factor kB in vivo selectively protects the murine small intestine against ionising radiationinduced damage. Cancer Res. 2004;64:6240-6246.
38. Abdel-Latif MM, O'Riordan J, Windle HJ, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239:491-500.
39. Russo SM, Tepper JE, Baldwin AS Jr, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys. 2001;50:183-193.
40. Rodel C, Haas J, Groth A, et al. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys. 2003;55:1341-1347.
41. Buchholz TA, Stivers DN, Stec J, et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 2002;8:461-468.
42. Chang JC, Hilsenbeck SG, Fuqua SA. Genomic approaches in the management and treatment of breast cancer. Br J Cancer. 2005;92:618-624.
43. Roblick UJ, Auer G. Proteomics and clinical surgery. Br J Surg. 2005;92:1464-1465.
44. Rai AJ, Stemmer PM, Zhang Z, et al. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics. 2005;5:3467-3474.
45. Blagosklonny MV. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene. 2004;23:2967-2975.
46. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003;4:721-729.
47. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene. 2004;23:2797-2808.
48. Pommier Y, Sordet O, Antony S, et al. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 2004;23:2934-2949.
49. Rodel C, Grabenbauer GG, Papadopoulos T, et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys. 2002;52:294-303.
50. Kremer A, Wilkowski R, Holdenrieder S, et al. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumor Biol. 2005;26: 44-49.
51. Holdenrieder S, Holubec L, Topolcan O, et al. Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy. Anticancer Res. 2005;25:1795-1801.
52. Rai AJ, Stemmer PM, Zhang Z, et al. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics. 2005;5:3467-3474.